348 related articles for article (PubMed ID: 25950192)
1. Molecular mechanism of statin-mediated LOX-1 inhibition.
Biocca S; Iacovelli F; Matarazzo S; Vindigni G; Oteri F; Desideri A; Falconi M
Cell Cycle; 2015; 14(10):1583-95. PubMed ID: 25950192
[TBL] [Abstract][Full Text] [Related]
2. Design of a novel LOX-1 receptor antagonist mimicking the natural substrate.
Falconi M; Ciccone S; D'Arrigo P; Viani F; Sorge R; Novelli G; Patrizi P; Desideri A; Biocca S
Biochem Biophys Res Commun; 2013 Aug; 438(2):340-5. PubMed ID: 23892036
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption.
Matarazzo S; Quitadamo MC; Mango R; Ciccone S; Novelli G; Biocca S
Mol Pharmacol; 2012 Aug; 82(2):246-54. PubMed ID: 22570368
[TBL] [Abstract][Full Text] [Related]
4. Structural implication for the impaired binding of W150A mutant LOX-1 to oxidized low density lipoprotein, OxLDL.
Nakano S; Sugihara M; Yamada R; Katayanagi K; Tate S
Biochim Biophys Acta; 2012 May; 1824(5):739-49. PubMed ID: 22369967
[TBL] [Abstract][Full Text] [Related]
5. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1.
Li D; Chen H; Romeo F; Sawamura T; Saldeen T; Mehta JL
J Pharmacol Exp Ther; 2002 Aug; 302(2):601-5. PubMed ID: 12130721
[TBL] [Abstract][Full Text] [Related]
6. Exploring the druggability of oxidized low-density lipoprotein (ox-LDL) receptor, LOX-1, a proatherogenic drug target involved in atherosclerosis.
Tomar A; Sahoo S; Aathi M; Kuila S; Khan MA; Ravi GRR; Jeyaraman J; Mehta JL; Varughese KI; Arockiasamy A
Biochem Biophys Res Commun; 2022 Oct; 623():59-65. PubMed ID: 35872543
[TBL] [Abstract][Full Text] [Related]
7. Surface plasmon resonance study on functional significance of clustered organization of lectin-like oxidized LDL receptor (LOX-1).
Ohki I; Amida H; Yamada R; Sugihara M; Ishigaki T; Tate S
Biochim Biophys Acta; 2011 Feb; 1814(2):345-54. PubMed ID: 21035571
[TBL] [Abstract][Full Text] [Related]
8. Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects.
Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Sawamura T; Gioffre WR; Auteri A; Puccetti L
Clin Appl Thromb Hemost; 2005 Oct; 11(4):417-28. PubMed ID: 16244767
[TBL] [Abstract][Full Text] [Related]
9. Protamine may have anti-atherogenic potential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1.
Takemura Y; Okamoto M; Hasegawa M; Hatanaka K; Kubota S
Biosci Biotechnol Biochem; 2019 Jun; 83(6):1094-1101. PubMed ID: 30871430
[TBL] [Abstract][Full Text] [Related]
10. [Effect and mechanism of PCSK9 on lectin-like oxidized low-density lipoprotein receptor-1 mediated oxidized low-density lipoprotein uptake by THP-1 derived macrophages].
Bao HL; Liao FJ; Fang L; Zhong F; Liu W; Li JQ
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 May; 47(5):367-373. PubMed ID: 31142080
[No Abstract] [Full Text] [Related]
11. Lectin-like oxidized low-density lipoprotein receptor 1 mediates matrix metalloproteinase 3 synthesis enhanced by oxidized low-density lipoprotein in rheumatoid arthritis cartilage.
Kakinuma T; Yasuda T; Nakagawa T; Hiramitsu T; Akiyoshi M; Akagi M; Sawamura T; Nakamura T
Arthritis Rheum; 2004 Nov; 50(11):3495-503. PubMed ID: 15529384
[TBL] [Abstract][Full Text] [Related]
12. The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization.
Biocca S; Filesi I; Mango R; Maggiore L; Baldini F; Vecchione L; Viola A; Citro G; Federici G; Romeo F; Novelli G
J Mol Cell Cardiol; 2008 Mar; 44(3):561-70. PubMed ID: 18191942
[TBL] [Abstract][Full Text] [Related]
13. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation.
Li DY; Chen HJ; Mehta JL
Cardiovasc Res; 2001 Oct; 52(1):130-5. PubMed ID: 11557241
[TBL] [Abstract][Full Text] [Related]
14. The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding.
Francone OL; Tu M; Royer LJ; Zhu J; Stevens K; Oleynek JJ; Lin Z; Shelley L; Sand T; Luo Y; Kane CD
J Lipid Res; 2009 Mar; 50(3):546-555. PubMed ID: 18845619
[TBL] [Abstract][Full Text] [Related]
15. Association of angiotensin II receptor 1 and lectin-like oxidized low-density lipoprotein receptor-1 mediates the cardiac hypertrophy induced by oxidized low-density lipoprotein.
Zhao Y; Li Y; Ning X; Chen K; Zhang S
Biochem Biophys Res Commun; 2017 Aug; 490(1):55-61. PubMed ID: 28595908
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
Kang BY; Mehta JL
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of LOX-1 by statins may relate to upregulation of eNOS.
Mehta JL; Li DY; Chen HJ; Joseph J; Romeo F
Biochem Biophys Res Commun; 2001 Dec; 289(4):857-61. PubMed ID: 11735125
[TBL] [Abstract][Full Text] [Related]
18. Arsenic augments the uptake of oxidized LDL by upregulating the expression of lectin-like oxidized LDL receptor in mouse aortic endothelial cells.
Hossain E; Ota A; Karnan S; Damdindorj L; Takahashi M; Konishi Y; Konishi H; Hosokawa Y
Toxicol Appl Pharmacol; 2013 Dec; 273(3):651-8. PubMed ID: 24145059
[TBL] [Abstract][Full Text] [Related]
19. Induced expression of lectin-like oxidized ldl receptor-1 in vascular smooth muscle cells following Chlamydia pneumoniae infection and its down-regulation by fluvastatin.
Prochnau D; Rödel J; Prager K; Kuersten D; Heller R; Straube E; Figulla HR
Acta Microbiol Immunol Hung; 2010 Jun; 57(2):147-55. PubMed ID: 20587387
[TBL] [Abstract][Full Text] [Related]
20. Role of oxidized LDL and lectin-like oxidized LDL receptor-1 in cerebral vasospasm after subarachnoid hemorrhage.
Matsuda N; Ohkuma H; Naraoka M; Munakata A; Shimamura N; Asano K
J Neurosurg; 2014 Sep; 121(3):621-30. PubMed ID: 24949677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
